Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.
Section of Cardiology Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Curr Atheroscler Rep. 2021 Jul 6;23(9):50. doi: 10.1007/s11883-021-00952-1.
This review highlights late-breaking science presented at the Virtual American College of Cardiology Scientific Sessions 2021 that demonstrated advancements in preventative cardiology and introduced novel therapeutic modalities for the management of chronic kidney disease, heart failure, and COVID-19.
The studies reviewed include clinical trials that assessed the use of dapagliflozin in patients with respiratory failure due to COVID-19 (DARE-19 trial); evinacumab for patients with severe hypertriglyceridemia and pancreatitis; effect of genotype-guided oral P2y12 inhibitors vs conventional clopidogrel on long-term ischemic outcomes after percutaneous coronary intervention (TAILOR-PCI trial); anticoagulation in patients hospitalized with COVID-19 (ACTION trial); atorvastatin vs placebo in patients with COVID-19 admitted to the ICU (INSPIRATION-S trial); rehabilitation therapy in older acute heart failure patients (REHAB-HF trial); and aspirin dosing: a patient-centric trial assessing benefits and long-term effectiveness (ADAPTABLE trial). In addition, we review the results of the American College of Cardiology Global Heart Attack Initiative (GHATI). Finally, we discuss the secondary analysis of the STRENGTH trial assessing the association of achieved levels of omega-3 fatty acid levels and major cardiovascular outcomes. The studies presented at the virtual American College of Cardiology Scientific Session 2021 represent remarkable contributions in the field of cardiovascular disease and prevention.
本文重点介绍了 2021 年虚拟美国心脏病学会科学会议上发表的最新科学研究进展，这些研究在预防心脏病学方面取得了进展，并为慢性肾脏病、心力衰竭和 COVID-19 的治疗引入了新的治疗方法。
本文回顾的研究包括评估达格列净在 COVID-19 导致呼吸衰竭患者中应用的临床试验（DARE-19 试验）；依维莫司在严重高甘油三酯血症和胰腺炎患者中的应用；基因指导的口服 P2y12 抑制剂与常规氯吡格雷对经皮冠状动脉介入治疗后长期缺血结局的影响（TAILOR-PCI 试验）；COVID-19 住院患者的抗凝治疗（ACTION 试验）；COVID-19 重症监护病房患者阿托伐他汀与安慰剂对照（INSPIRATION-S 试验）；老年急性心力衰竭患者康复治疗（REHAB-HF 试验）；以及阿司匹林剂量：一项评估获益和长期有效性的患者为中心试验（ADAPTABLE 试验）。此外，我们还回顾了美国心脏病学会全球心脏病发作倡议（GHATI）的结果。最后，我们讨论了 STRENGTH 试验的二次分析结果，该分析评估了实现的ω-3 脂肪酸水平与主要心血管结局之间的关联。2021 年虚拟美国心脏病学会科学会议上发表的研究代表了心血管疾病预防领域的杰出贡献。
